Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Uterine Cervical Neoplasms 2

Interventions

pembrolizumab 3tisotumab vedotin 2Cisplatin 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1sacituzumab govitecan 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1larotrectinib 1ipatasertib 1erdafitinib 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1adavosertib 1X-Rays 1Vinorelbine 1Trastuzumab 1Topotecan 1Sunitinib 1Specimen Handling 1Saline Solution 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has announcements × Uterine Cervical Neoplasms × tisotumab vedotin × Clear all
NCT04697628 2026-02-24

innovaTV 301

Seagen Inc.

Phase 3 Completed
502 enrolled 18 charts 1 FDA
Gynecologic

Uterine Cervical Neoplasms

NCT03438396 2023-07-25

A Trial of Tisotumab Vedotin in Cervical Cancer

Seagen Inc.

Phase 2 Completed
102 enrolled 20 charts 1 FDA
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡